PALI - Latest News
Palisade Bio, Inc. (PALI), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $347.2M. Beta to the broader market is 1.54.
The article list below shows the most recent PALI headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent PALI Headlines
Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00
defenseworld.net - Aug 17, 2026
Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has received a consensus rating of "Buy" from the ten ratings firms that are covering the firm, M
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
globenewswire.com - Aug 10, 2026
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammat
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
benzinga.com - Jul 23, 2026
Oppenheimer on Thursday initiated coverage of Palisade Bio Inc. (NASDAQ:PALI) , saying the stock offers investors an attractive way to gain exposure
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
globenewswire.com - Jul 10, 2026
Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
globenewswire.com - Jul 10, 2026
Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI
How News Affects PALI Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PALI's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked PALI news questions
- What is the latest PALI news headline?
- The most recent PALI headline (Aug 17, 2026) is "Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the PALI news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What PALI news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual PALI options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.